Cellular Biomedicine Group to Present Phase IIa Results from CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced Diffuse Large B Cell Lymphoma

Cellular Biomedicine Group Inc.

("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that it would provide a meaningful update on its CD20 Chimeric Antigen Receptor T-cell (CAR-T) Phase IIa trial in Advanced, Refractory or Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) at the upcoming 4th International Conference on Translational Medicine to be held on October 26-28, 2015 in Baltimore, Maryland, USA. Title: Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell Non-Hodgkin's lymphoma: An early Phase IIa trial report Scientific Program: October 26, 2015 16:15-16:40 EDT Location: DoubleTree by Hilton Hotel Baltimore - BWI Airport, Chesapeake Hall Presenter: Yihong Yao, Ph.D., Chief Scientific Officer, Cellular Biomedicine Group Full details of the presented data will be available on the Company's website following the presentation.